Ratings changes for SpaceX, JetBlue Airways, Zscaler, Solstice Advanced Mat, Zscaler, Zscaler, Simulations Plus and more...

October 7th, 2026

Unsubscribe
 
 
MarketBeat Daily RatingsMy Portfolio
Unlock stock ideas, alerts, and portfolio tools with MarketBeat All Access.  Get All Access

Today's Top Stories

Rivian Escapes the EV Graveyard—But Can It Stay Alive?

Rivian Escapes the EV Graveyard—But Can It Stay Alive?

By Jeffrey Neal Johnson

Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI

Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI

By Chris Markoch

Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation

Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation

By Jeffrey Neal Johnson

Why The Biggest Names in AI Are Heading To The Arctic

Sponsored · Partner Content

Why The Biggest Names in AI Are Heading To The Arctic

Google contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros. One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028…

See why this overlooked company could be next in the spotlighttc pixel

Analysts' Upgrades

All Upgrades
AFYA Afya
JPMorgan Chase & Co.
Neutral → Overweight
PT $21.00 → $19.00
36.6% upside
HUM Humana
Cantor Fitzgerald
Neutral → Overweight
PT $300.00 → $460.00
13.2% upside
MC Moelis & Company
UBS Group
Sell → Neutral
PT $59.00
5.2% upside

FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial

Sponsored · Partner Content

This Biotech Just Got FDA Clearance for a New MS Treatment

A NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple sclerosis therapy, Lucid-MS, to enter Phase 2 clinical trials - the first time it will be tested in patients with progressive MS. Unlike treatments that suppress the immune system, Lucid-MS is designed to protect myelin, the insulating layer destroyed by the disease…

See why this FDA clearance could be a defining catalysttc pixel

Analysts' Downgrades

All Downgrades
OC Owens Corning
Vertical Research
Hold → Sell
PT $106.00
11.5% downside
UWMC UWM
Keefe, Bruyette & Woods
Outperform → Market Perform
PT $1.50
25.5% upside

You Could Qualify for This Overseas Citizenship By Mail

Sponsored · Partner Content

You Could Qualify for This Overseas Citizenship By Mail

A new citizenship law has reportedly granted millions of Americans eligibility for dual citizenship. Qualifying could mean access to universal healthcare, a backup passport for you and your family, and a fast, no-flight exit route from the U.S.

See if you could qualify for a second passport in minutestc pixel

Analysts' New Coverage

All Initiations
ABT Abbott Laboratories
Barclays
Overweight
PT $120.00
22.3% upside
AJG Arthur J. Gallagher & Co.
Oppenheimer
Market Perform
BAX Baxter International
Barclays
Underweight
PT $20.00
17.7% downside
DK Delek US
Freedom Broker
Hold
PT $86.00
13.5% upside
FOSL Fossil Group
Lake Street Capital
Buy
PT $10.00
41.6% upside
MMED MiniMed Group
Barclays
Equal Weight
PT $22.00
12.0% upside
SAIL SailPoint
Oppenheimer
Outperform
PT $30.00
50.7% upside
SENS Senseonics Holdings, Inc. Common Stock
Barclays
Equal Weight
PT $10.00
0.4% upside
STVN Stevanato Group
Deutsche Bank Aktiengesellschaft
Hold
SVRA Savara
JPMorgan Chase & Co.
Overweight
PT $12.00
158.1% upside
TMDX TransMedics Group
Barclays
Overweight
PT $120.00
49.5% upside

The AI tool that beat Berkshire Hathaway in backtests – Claim Free Access

Sponsored · Partner Content

The AI tool that beat Berkshire Hathaway in backtests – Claim Free Access

One AI tool outperformed Berkshire Hathaway by 347 percent in backtests, correctly calling 71 percent of its trades across the toughest markets in a generation, including the 2020 crash, 2022 bear market, and 2025 tariff turmoil. TradeSmith CEO Keith Kaplan built the model using TimeGPT, generating a monthly rotation of five top ranked stocks without daily monitoring or manual timing…

Claim free access to the AI tool's September stock picks nowtc pixel
MarketBeat All Access

Every research tool in one place

MarketBeat All Access gives you the full suite of research tools, real-time alerts, and analyst ratings — everything you need to invest with confidence.

Get MarketBeat All Access

More Stories

Why onsemi’s Synaptics Pivot Could Be a Game Changer

Why onsemi’s Synaptics Pivot Could Be a Game Changer

By Thomas Hughes

Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion

Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion

By Jeffrey Neal Johnson

Only 20 Stocks Are Holding Up the Market (3 Buy the Dip Stocks Outside of AI)

Only 20 Stocks Are Holding Up the Market (3 Buy the Dip Stocks Outside of AI)

Thank you for subscribing to MarketBeat!
MarketBeat empowers everyday investors to make better investment decisions by providing real-time financial information and independent investment analysis.
 
If you need assistance with your subscription, please feel free to contact MarketBeat's U.S. based support team at contact@marketbeat.com.
 
If you wish to opt out or update which emails you receive, you may update your mailing preferences or unsubscribe from this newsletter.
 
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl. #620, Sioux Falls, S.D. 57103-7078. USA..
 
From Our Partners: The AI tool that beat Berkshire Hathaway in backtests – Claim Free Access (From TradeSmith)